Wednesday, 13 March 2019 22:52

IBM Research finds way to detect Alzheimer's disease early via ML-based blood test Featured


Australian researchers for global tech company IBM have applied machine learning to identify proteins in blood that can predict Alzheimer’s disease risk.

Alzheimer’s disease is a terminal neurodegenerative disease that has historically been diagnosed based on observing significant memory loss. There is currently no cure or disease-modifying therapy, despite hundreds of clinical trials.

It is thought these trials may have a high failure rate because the people enrolled are in the last stages of the disease, likely already suffering a level of brain tissue loss that cannot easily be repaired.

Thus, researchers have put their mind to how to detect this disease earlier, while a chance may still exist to slow its progression.

Recent research has shown a biological marker associated with the disease, a peptide called amyloid-beta, changes decades before any memory-related issues are apparent. Examining the concentration of the peptide in a person’s spinal fluid can provide an indication of Alzheimer’s disease risk decades before any memory-related issues are apparent.

Yet, accessing spinal fluid is highly invasive, requires an anaesthetist and is expensive.

IBM researchers released a paper this week detailing their work in employing machine learning to identify a set of proteins in blood that can predict the concentration of amyloid-beta in spinal fluid.

That is, the work could one day help clinicians predict the risk of Alzheimer’s in their patients, decades prior to any memory effects, through a simple and routine blood test.

The study isn’t the only one exploring a blood test for Alzheimer’s, but it is the first to use a machine learning approach to identify sets of proteins in blood that are predictive of a biomarker in spinal fluid.

The research is still in its early phases, but could potentially help improve the selection of individuals for Alzheimer’s disease drug trials, and the machine learning approach can be extended to model other spinal fluid-based biomarkers.

The researchers will present their work on a blood test for another key Alzheimer’s biomarker, tau, in Lisbon during a conference from 26 to 31 March.


Did you know: 1 in 10 mobile services in Australia use an MVNO, as more consumers are turning away from the big 3 providers?

The Australian mobile landscape is changing, and you can take advantage of it.

Any business can grow its brand (and revenue) by adding mobile services to their product range.

From telcos to supermarkets, see who’s found success and learn how they did it in the free report ‘Rise of the MVNOs’.

This free report shows you how to become a successful MVNO:

· Track recent MVNO market trends
· See who’s found success with mobile
· Find out the secret to how they did it
· Learn how to launch your own MVNO service


David M Williams

David has been computing since 1984 where he instantly gravitated to the family Commodore 64. He completed a Bachelor of Computer Science degree from 1990 to 1992, commencing full-time employment as a systems analyst at the end of that year. David subsequently worked as a UNIX Systems Manager, Asia-Pacific technical specialist for an international software company, Business Analyst, IT Manager, and other roles. David has been the Chief Information Officer for national public companies since 2007, delivering IT knowledge and business acumen, seeking to transform the industries within which he works. David is also involved in the user group community, the Australian Computer Society technical advisory boards, and education.



Recent Comments